Recommendations for testing of predictive marker HER2 in patients with invasive breast cancer. Recommendations in accordance with American Society of Clinical Oncology (ASCO) guidelines from 30th May 2018
Oncology in Clinical Practice · 25.11.2018 · 14 (5) · 272-277
DOI: 10.5603/ocp.2018.0034 ↗Kurz gefasst
Leitlinie in der Zeitschrift Oncology in Clinical Practice, online erschienen am 25.11.2018. Verfasst von Andrzej Marszałek und 1 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Marszałek, A., & Krzakowski, M. (2018). Recommendations for testing of predictive marker HER2 in patients with invasive breast cancer. Recommendations in accordance with American Society of Clinical Oncology (ASCO) guidelines from 30th May 2018. Oncology in Clinical Practice, 14(5), 272-277. https://doi.org/10.5603/ocp.2018.0034
Vancouver
Marszałek A, Krzakowski M. Recommendations for testing of predictive marker HER2 in patients with invasive breast cancer. Recommendations in accordance with American Society of Clinical Oncology (ASCO) guidelines from 30th May 2018. Oncology in Clinical Practice. 2018;14(5):272-277. doi:10.5603/ocp.2018.0034
BibTeX
@article{Marszaek2018,
author = {Marszałek, Andrzej and Krzakowski, Maciej},
title = {Recommendations for testing of predictive marker HER2 in patients with invasive breast cancer. Recommendations in accordance with American Society of Clinical Oncology (ASCO) guidelines from 30th May 2018},
journal = {Oncology in Clinical Practice},
year = {2018},
volume = {14},
number = {5},
pages = {272--277},
doi = {10.5603/ocp.2018.0034}
}
EUVIMED